Antiretroviral therapy adherence in resource-limited and resource-rich settings: Current status of knowledge and research priorities

Therapy

Volumn 4, Issue 6, 2007, Pages 775-786

  Nachega, Jean B ^a,b   Mills, Edward J ^c,d  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c ST PAUL S HOSPITAL   (Canada)

^d SIMON FRASER UNIVERSITY   (Canada)

Author keywords

Adherence; AIDS; Antiretroviral therapy; Developed countries; Developing countries; HAART; HIV infection

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; NEVIRAPINE; PEDIMMUNE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; ZIDOVUDINE;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DIRECTLY OBSERVED THERAPY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE DISTRIBUTION; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; LIVER TOXICITY; PATIENT ATTITUDE; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PUBLIC HEALTH; RESOURCE MANAGEMENT; REVIEW; SURVIVAL RATE; TREATMENT DURATION; TREATMENT FAILURE; UNITED NATIONS; UNSPECIFIED SIDE EFFECT; WORLD HEALTH ORGANIZATION;

EID: 38049166008     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.2217/14750708.4.6.775     Document Type: Review

References (81)

1. Kovacs JA, Masur H: Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. N. Engl. J. Med. 342(19), 1416-1429 (2000).
2. Palella FJ Jr, Delaney KM, Moorman AC et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 338(13), 853-860 (1998).
3. Mocroft A, Vella S, Benfield TL et al.: Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 352(9142), 1725-1730 (1998).
4. Moore RD, Chaisson RE: Natural history of HIV infection in the era of combination antiretrovirai therapy. AIDS 13(14), 1933-1942 (1999).
5. Connor EM, Sperling RS, Gelber R et al.: Reduction of maternal-Infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N. Engl. J. Med. 331(18). 1173-1180 (1994).
6. Peckham C, Newell ML: Preventing vertical transmission of HIV infection. N. Engl. J. Med. 343(14), 1036-1037 (2000).
7. Quinn TC, Wawer MJ, Sewankambo N et al.: Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N. Engl. J. Med. 342(13), 921-929 (2000).
8. Harries AD, Schouten EJ, Makombe SD et al.: Ensuring uninterrupted supplies of antiretroviral drugs in resource-poor settings: an example from Malawi. Bull. WHO 85(2), 152-155 (2007).
9. Stringer JS, Zulu I, Levy J et al.: Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 296(7), 782-793 (2006).
10. Severe P, Leger P, Charles M et al.: Antiretroviral therapy in a thousand patients with AIDS in Haiti. N. Engl. J. Med. 353(22), 2325-2334 (2005).
11. Braitstein P, Brinkhof MW, Dabis F et al.: Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 367, 817-824 (2006).
12. Lucas GM, Chaisson RE, Moore RD: Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann. Intern. Med. 131, 81-87 (1999).
13. Paterson DL, Swindells S, Mohr J et al.: Adherence to protease Inhibitor therapy and outcomes in patients with HIV infection. Ann. Intern. Med. 133(1), 21-30 (2000).
14. Arnsten JH, Demas PA, Farzadegan H et al.: Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin. Infect. Dis. 33, 1417-1423 (2001).
15. Bangsberg DR, Charlebois ED, Grant RM et al.: High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS 17, 1925-1932 (2003).
16. Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE: Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin. Infect. Dis. 37, 1112-1118 (2003).
17. Harrigan PR, Hogg RS, Dong WW et al.: Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J. Infect. Dis. 191, 339-347 (2005).
18. Bangsberg DR, Perry S, Charlebois ED et al.: Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 15. 1181-1183 (2001).
19. Hogg RS, Heath K, Bangsberg D et al.: Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS 16, 1051-1058 (2002).
20. Nachega JB, Hislop M, Dowdy DW et al.: Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J. Acquir. Immune. Defic. Syndr. 43, 78-84 (2006).
21. Wood E, Hogg RS, Yip B. Moore D, Harrigan PR, Montaner JS: Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts 2200 cells/μl. AIDS 20, 1117-1123 (2006).
22. Mullan F, Frehywot S: Non-physician clinicians in 47 sub-Saharan African countries. Lancet doi:10.1016/S0140-6736(07)60785-5 (2007) (Epub ahead of print).
23. Schrecker T, Labonte R: Taming the brain drain: a challenge for public health systems in Southern Africa. Int. J. Occup. Environ. Health 10, 409-415 (2004).
24. Spence D, Merriman A. Binagwaho A: Palliative care in Africa and the Caribbean. PLoS Med. 1, E5 (2004).
25. Friedland GH: HIV medication adherence. The intersection of biomedical, behavioral, and social science research and clinical practice. J. Acquir. Immune Defic. Syndr. 43(1), S3-S9 (2006).
26. Bangsberg DR: Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin. Infect. Dis. 43(7), 939-941 (2006).
27. Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G: Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann. Intern. Med. 146(8), 564-573 (2007).
28. Hugen PW, Langebeek N, Burger DM et al.: Assessment of adherence to HIV protease inhibitors: comparison and combination of various methods, including MEMS (electronic monitoring), patient and nurse report, and therapeutic drug monitoring. J. Acquir. Immune Defic. Syndr. 30, 324-334 (2002).
29. Liu H, Golin CE, Miller LG et al.: A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann. Intern. Med. 134,968-977 (2001).
30. Nieuwkerk PT, Oort FJ: Self-reported adherence to antiretroviral therapy for HIV-1 infection and virologic treatment response: a meta-analysis. J. Acquir. Immune Defic. Syndr. 38. 445-448 (2005).
31. Chesney MA: The elusive gold standard. Future perspectives for HIV adherence assessment and intervention. J. Acquir. Immune Defic. Syndr. 43(1), S149-S155 (2006).
32. Miller LG, Hays RD: Measuring adherence to antiretroviral medications in clinical trials. HIV Clin. Trials. 1, 36-46 (2001).
33. Bangsberg DR: Monitoring adherence to HIV antiretroviral therapy in routine clinical practice: the past, the present, and the future. AIDS Behav. 10, 249-251 (2006).
34. Mills EJ, Nachega JB, Buchan I et al.: Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 296(6), 679-690 (2006).
35. Deeks SG: Treatment of antiretorviral drug-resistant HIV-1 Infection. Lancet 362, 2002-(2003).
36. Oyugi JH, Byakika-Tusüme J, Charlebois ED et al.: Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. J. Acquir. Immune Defic. Syndr. 36, 1100-1102 (2004).
37. Wainberg MA, Friedland G: Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 279(24), 1977-1983 (1998).
38. Chesney MA, Ickovics J, Hecht FM. Sikipa G, Rabkin J: Adherence: a necessity for successful HIV combination therapy. AIDS 13(Suppl. A), S271-S278 (1999),
39. Stone VE: Strategies for optimizing adherence to highly active antiretroviral therapy: lessons from research and clinical practice. Clin. Infect. Dis. 33(6), 865-872 (2001).
40. Bangsberg DR, Hecht FM, Charlebois ED et al.: Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 14(4). 357-366 (2000).
41. Attaran A, Freedburg KA, Hirsch M: Dead wrong on AIDS. Washington Post. 15 June (2001).
42. Hogg R, Cahn P, Katabira ET et al.: Time to act: global apathy towards HIV/AIDS is a crime against humanity. Lancet 360, 1710-1711 (2002).
43. Orrell C, Bangsberg DR, Badri M, Wood R: Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS 17(9), 1369-1375 (2003).
44. Nachega JB, Steth DM, Lehman DA et al.: Adherence to antiretroviral therapy in HIV-infected adults in Soweto, South Africa. AIDS Res. Hum Retroviruses. 20(10), 1053-1056 (2004).
45. Hardon AP, Akurut D, Comoro C et al.: Hunger, waiting time and transport costs: time to confront challenges to ART adherence in Africa. AIDS Care 19(5), 658-665 (2007).
46. Gill CJ, Hamer DH, Simon JL, Thea DM, Sabin LL: No room for complacency about adherence to antiretroviral therapy in sub-Saharan Africa. AIDS 19(12), 1243-1249 (2005).
47. Laurent C, Ngom Gueye NF, Ndour CT. et al.: for the ANRS 1215/1290 Study Group: Long-term benefits of highly active antiretroviral therapy in Senegalese HIV-1-infected adults. J. Acquir. Immune Defic. Syndr. 38(1), 14-17 (2005).
48. Oyugi JH, Byakika-Tuslime J, Ragland K et al.: Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS 21, 965-971 (2007).
49. Mills EJ, Nachega JB, Bangsberg DR et al.: Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med. 3(11), E438 (2006).
50. Laurent C, Kouanfack C, Koulla-Shiro S et al.: Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet 364, 29-34 (2004).
51. Crane JT, Kawuma A, Oyugi JH et al.: The price of adherence: qualitative findings from HIV positive individuals purchasing fixed-dose combination generic HIV antiretroviral therapy in Kampala, Uganda. AIDS Behav. 10(4), 437-442 (2006).
52. Weiser S, Wolfe W, Bangsberg D et al.: Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. J. Acquir. Immune Defic. Syndr. 34, 281-288 (2003).
53. Laniece I, Ciss M. Desclaux A et al.: Adherence to HAART and its principal determinants in a cohort of Senegalese adults. AIDS 17(Suppl. 3), S103-S108 (2003).
54. Myer L, Morrow C, Nachega J, Cooper D: HIV-infected women in ART programmes. Lancet 365, 655-656 (2005).
55. Orrell C: Antiretroviral adherence in a resourre-poor setting. Curr. HIV/AIDS Rep. 2, 171-176 (2005).
56. Bangsberg DR, Mundy LM, Tulsky JP: Expanding directly observed therapy: tuberculosis to human immunodeficiency virus. Am. J. Med. 110(8), 664-666 (2001).
57. Volmink J, Garner P: Directly observed therapy for treating tuberculosis. Cochrane Database Syst. Rev. CD003343 (2006).
58. Wohl AR, Garland WH, Valencia R et al.: A randomized trial of directly administered antiretroviral therapy and adherence case management Intervention. Clin. Infect. Dis. 42, 1619-1627 (2006).
59. Kirkland LR, Fischl MA, Tashlma KT et al.: Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment. Clin. Intect. Dis. 34(4). 511-518 (2002).
60. Altice FL, Maru DS, Bruce RD, Springer SA, Friedland GH: Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trial. Clin. Infect. Dis. 45(6), 770-778 (2007).
61. Chowdhury AM. Chowdhury S, Islam MN, Islam A, Vaughan JP: Control of tuberculosis by community health workers in Bangladesh. Lancet 350, 169-70 (1997).
62. Wilkinson D, Davies GR, Connolly C, Directly observed therapy for tuberculosis in rural South Africa, 1991 through 1994. Am. J. Public Health 86(8 Pt 1), 1094-1097 (1996).
63. Newell JN, Baral SC, Pande SB, Barn DS, Malla P: Family-member DOTS and community DOTS for tuberculosis control in Nepal: cluster-randomized controlled trial. Lancet 367, 903-909 (2006).
64. Cavalcante SC, Soares EC, Pacheco AG, Chaisson RE, Durovni B, DOTS Expansion Team: Community DOT for tuberculosis in a Brazilian favela: comparison with the clinic model. Int. J. Tuberc. Lung Dis. 11 (5), 544-549 (2007).
65. Farmer P, Leandre F, Mukherjee JS et al.: Community-based approaches to HIV treatment in resource-poor settings. Lancet 358(9279), 404-409 (2001).
66. Pearson CR, Micek M, Simoni JM, Matediana E, Martin DP, Gloyd S: Modified directly observed therapy to facilitate highly active antiretroviral therapy adherence in Beira, Mozambique. Development and implementation. J. Acquir. Immune Defic. Syndr. 43(Suppl. 1), S134-S141 (2006).
67. Bussmann H, Wester C, Thomas A et al.: HAART outcomes among HIV-1C-infected adults in Botswana: interim results from a randomized clinical trial. Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, USA, February 25-28 (2007) (Abstract 507).
68. Simoni JM, Pearson CR, Pantalone DW, Marks G, Crepaz N: Efficacy of interventions in improving highly active antiretroviral therapy adherence and HIV-1 RNA viral load. A meta-analytic review of randomized controlled trials. J. Acquir. Immune Defic. Syndr. 43 (Suppl. 1), S23-S35 (2006).
69. Rueda S, Park-Wyllie LY, Bayoumi AM et al.: Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS Cochrane Database Syst. Rev. 3, CD00144 (2006).
70. Petersen ML, Wang Y, van der Laan MJ et al.: Pillbox organizers are associated with improved adherence to HIV antiretroviral therapy and viral suppression: a marginal structural model analysis. Clin. Infect. Dis., 45, 908-915 (2007).
71. Puccio JA, Belzer M, Olson J et al.: The use of cell phone reminder calls for assisting HIV-Infected adolescents and young adults to adhere to highly active antiretroviral therapy: a pilot study. AIDS Patient Care STDS 20(6), 438-444 (2006).
72. Donald S, Ulrike R, Charissa B, Skinner D: Evaluation of use of cellphones to aid compliance with drug therapy for HIV patients. AIDS Care 19 (5), 605-607 (2007).
73. Green D: South Africa: a novel approach to improving adherence to TB treatment. Essent. Drugs Monit. 33, 8 (2003).
74. Bikaako-Kajura W, Luyirika E, Purcell DW et al.: Disclosure of HIV status and adherence to daily drug regimens among HIV-infected children in Uganda. AIDS Behav. 10, S85-S93 (2006).
75. Nabukeera-Barungi N, Kalyesubula I, Kekitiinwa A, Byakika-Tusiime J, Musoke P: Adherence to antiretroviral therapy in children attending Mulago Hospital, Kampala. Ann Trop. Paediatr. 27, 123-131 (2007).
76. Simoni JM, Montgomery A, Martin E, New M, Demas PA, Rana S: Adherence to antiretroviral therapy for pediatric HIV infection: a qualitative systematic review with recommendations for research and clinical management. Pediatrics 119(6). E1371-E1383 (2007).
77. Nyandiko WM, Ayaya S, Nabakwe E et al.: Outcomes of HIV-infected orphaned and non-orphaned children on antiretroviral therapy in western Kenya. J. Acquir. Immune Defic. Syndr. 43, 418-425 (2006).
78. Freedberg KA, Losina E, Weinstein MC et al.: The cost effectiveness of combination antiretroviral therapy for HIV disease. N. Engl. J. Med. 344(11), 824-831 (2001).
79. Bishat D, Colchero MA, Durack D: Modeling the cost effectiveness of antiretroviral treatment strategies in low income settings. AIDS 21(10), 1333-1340 (2007).
80. Badri M, Cleary S, Maartens G et al.: When to initiate HAART in sub-Saharan Africa? A South African cost-effectiveness study. Antivir. Ther. 11 (1), 63-72 (2006).
81. Freedberg KA, Hirschorn LR, Schackman BR et al.: Cost-effectiveness of an intervention to improve adherence to antiretroviral therapy in HIV-infected patients. J. Acquir. Immune Defic. Syndr. 43(Suppl. 1), S113-S118 (2006).